Atypical Wiskott-Aldrich syndrome presenting with normal platelet volume and end-stage renal disease: from misdiagnosis as ITP to combined transplantation Authors: Guan Zhaojie, Chen Hua, Wu Zhenghua, Zhao Pengfei, Tong Xunan, Wu Kang, Zhou Tianyu, Liu Bin Published: 2026 ABSTRACT We report a 30-year-old male with a novel WAS mutation (c.252C > A, p.F84L) who was misdiagnosed with immune thrombocytopenia (ITP) for years. Despite persistent thrombocytopenia, his mean platelet volume remained normal, an atypical feature of Wiskott-Aldrich syndrome (WAS). His course was complicated by stage-5 chronic kidney disease, renal anemia, IgA nephropathy, and recurrent infections. Laboratory tests consistently showed low lymphocyte counts and reduced WAS protein (WASp) levels. After confirming WAS, the original plan of kidney transplantation alone was changed to combined hematopoietic stem cell and kidney transplantation to restore immunity and reduce graft failure risk. This case highlights that WAS can present with normal platelet volume; thus, WAS should be considered in patients with unexplained chronic kidney disease, recurrent infections, and poor ITP therapy response, even without typical microthrombocytopenia. Introduction Wiskott-Aldrich syndrome (WAS) is a severe X-linked recessive genetic disorder caused by mutations in the WAS gene and predominantly affects males [1]. The disease is characterized by the triad of thrombocytopenia, eczema, and recurrent infections [2], and it also significantly increases the risk of autoimmune diseases and malignancies. According to the literature, approximately 19% of patients with WAS develop kidney disease [3].Although reduced platelet volume is a characteristic finding in most patients with WAS, numerous cases [4,5] with normal platelet volume have also been reported in the literature.WAS typically manifests in early childhood. The protein encoded by the WAS gene, WASp, plays a broad regulatory role in hematopoietic lineages, thereby ensuring the normal progression of immune processes [6]. Due to immune system defects, patients with WAS are often complicated by recurrent infections and autoimmune diseases. Currently, hematopoietic stem cell transplantation is the internationally recognized curative treatment. However, recent reports [7] have indicated that gene therapy has achieved favorable outcomes in adult patients with WAS.Previous case [8] reports have demonstrated that the use of immunosuppressants in patients with WAS and stage 5 chronic kidney disease after renal transplantation may lead to multiple infections and an increased risk of malignancies. Therefore, for such patients who require renal transplantation, the surgical risks and the use of immunosuppressive agents must be carefully weighed. In this study, we report the diagnostic process of an adult patient with WAS who had been misdiagnosed with ITP for a prolonged period and presented with an atypical WAS phenotype complicated by stage 5 chronic kidney disease. Furthermore, we propose a potential curative strategy for WAS patients who have reached stage 5 chronic kidney disease: combined hematopoietic stem cell and renal transplantation. This approach aims to correct the underlying immune defect of WAS and establish graft immune tolerance, thereby reducing the risk of immune rejection. Methods Genomic DNA was extracted from peripheral whole blood samples collected in tubes containing ethylenediaminetetraacetic acid (EDTA) and sent to a sequencing company (Guangzhou MED-MAX Medical Laboratory Co., Ltd.) for whole-exome sequencing (WES) and Sanger sequencing. Bone marrow aspiration (BMA) and biopsy were performed using standard techniques. Morphologic analysis was conducted by two independent hematopathologists. Flow cytometric immunophenotyping of bone marrow cells was performed using a panel of antibodies against CD45, CD34, CD117, CD13, CD33, CD3, CD19, and CD56. WASp expression levels in peripheral blood mononuclear cells (PBMCs) were quantified by flow cytometry using a mouse anti-human WASp monoclonal antibody (clone 5A5, BD Biosciences). Result Chronological clinical course The clinical course of the patient is summarized in Fig. 1 (Timeline) and key laboratory parameters are presented in Table 1.Fig. 1Family pedigree and Sanger sequencing of the WAS gene mutation. (I) Family pedigree showing X-linked recessive inheritance. Squares represent males, circles represent females, filled symbols represent affected individuals, and half-filled symbols represent carrier females. (II) Sanger sequencing chromatograms confirming the c.252C > A (p.F84L) mutation in the patient (hemizygous) and his mother (heterozygous carrier). Chromosome designations: X1 = paternal normal X chromosome; X2 = maternal normal X chromosome; Xw = maternal X chromosome carrying the WAS mutation; Y = paternal Y chromosome.Table 1Key laboratory parameters over the clinical course.Table 1Time pointPlatelet count (×109/L)MPV (fL)Lymphocyte count (×109/L)Serum creatinine (μmol/L)Clinical event2000128.2Not available62Initial diagnosis of ITP2019188.71.32109Diagnosis of IgA nephropathy2023159.11.05566Diagnosis of CKD5Nov-25137.80.92767.8Admission for ESRD1st-Dec-2025197.31.61452.2Initiation of hemodialysis22nd-Dec-2025478.60.91275.2Bone marrow aspiration10th-Jan-2025889.30.74605AV fistula infection and sepsis Family pedigree and Sanger sequencing of the WAS gene mutation. (I) Family pedigree showing X-linked recessive inheritance. Squares represent males, circles represent females, filled symbols represent affected individuals, and half-filled symbols represent carrier females. (II) Sanger sequencing chromatograms confirming the c.252C > A (p.F84L) mutation in the patient (hemizygous) and his mother (heterozygous carrier). Chromosome designations: X1 = paternal normal X chromosome; X2 = maternal normal X chromosome; Xw = maternal X chromosome carrying the WAS mutation; Y = paternal Y chromosome. Table 1Key laboratory parameters over the clinical course.Table 1Time pointPlatelet count (×109/L)MPV (fL)Lymphocyte count (×109/L)Serum creatinine (μmol/L)Clinical event2000128.2Not available62Initial diagnosis of ITP2019188.71.32109Diagnosis of IgA nephropathy2023159.11.05566Diagnosis of CKD5Nov-25137.80.92767.8Admission for ESRD1st-Dec-2025197.31.61452.2Initiation of hemodialysis22nd-Dec-2025478.60.91275.2Bone marrow aspiration10th-Jan-2025889.30.74605AV fistula infection and sepsis Key laboratory parameters over the clinical course. Table 1. Clinical timeline of the patient. The timeline illustrates the 25-year clinical course from initial presentation with thrombocytopenia in 2000 to the definitive diagnosis of WAS in 2026. Key events include the diagnosis of ITP, development of IgA nephropathy and progression to ESRD, initiation of hemodialysis, AV fistula creation and subsequent infection, and the revised treatment plan for combined transplantation. 2000–2019: Initial presentation and misdiagnosis of ITP In 2000, at 5 years of age, the patient presented with recurrent epistaxis and easy bruising. Complete blood count (CBC) revealed severe thrombocytopenia (platelet count 12 × 109/L) with a normal MPV of 8.2 fL. BMA showed increased megakaryocytes with maturation arrest, leading to a diagnosis of idiopathic thrombocytopenic purpura (ITP). He was treated with oral prednisone (1-2 mg/kg/day) for 6 years, which resulted in transient increases in platelet counts to 30-50 × 109/L. However, thrombocytopenia relapsed whenever steroids were tapered. Cyclosporine A (CsA) was added at 3 mg/kg/day for 3 months, which achieved a partial response (platelets 20-40 × 109/L) that could not be sustained after discontinuation. Over the subsequent 19 years, the patient was maintained on intermittent courses of corticosteroids and oral avatrombopag maleate. His platelet counts remained persistently low (10–20 × 109/L) with normal MPV (7.8–9.3 fL), and he experienced recurrent gingival bleeding and skin petechiae. No eczema or severe infections were noted during this period. 2019–2023: Development of chronic kidney disease In 2019, at 24 years of age, the patient presented with increased foamy urine. Laboratory evaluation showed serum creatinine 109 μmol/L, urine protein 2+, and microscopic hematuria with red blood cells (RBCs) too numerous to count. A clinical diagnosis of IgA nephropathy was made based on the presence of glomerular hematuria and proteinuria in the absence of other identifiable causes. Renal biopsy was deferred due to the extremely high bleeding risk associated with severe thrombocytopenia. He was treated with losartan potassium 50 mg daily and traditional Chinese medicine preparations, which were discontinued after 2 weeks due to lack of efficacy. By 2023, his serum creatinine had increased to 566 μmol/L, consistent with CKD5. Repeat BMA was performed, which again showed megakaryocytic hyperplasia with maturation arrest, reaffirming the diagnosis of ITP. He was initiated on chronic kidney disease management including febuxostat 40 mg daily, compound α-ketoacid tablets 2.52 g four times daily, arotinolol 5 mg twice daily, roxadustat 20 mg three times weekly, and amlodipine 5 mg daily. 2025–2026: Hospitalization and definitive diagnosis In November 2025, at 30 years of age, the patient presented with 1 week of progressive bilateral lower extremity edema and decreased urine output, followed by 1 day of fatigue, nausea, and vomiting. Laboratory tests at an outside hospital revealed: hemoglobin 67 g/L, platelet count 13 × 109/L, serum creatinine 767.8 μmol/L, and blood urea nitrogen 32.9 mmol/L. He was transferred to our hospital for further management. On admission, physical examination showed chronic renal facies, pale conjunctivae, diffuse skin petechiae, and 3+ pitting edema of the lower extremities. No eczema or lymphadenopathy was noted. Initial CBC confirmed: white blood cell (WBC) count 7.7 × 109/L, neutrophil count 5.58 × 109/L, lymphocyte count 1.60 × 109/L (normal 1.10–3.20 × 109/L), hemoglobin 63 g/L, platelet count 19 × 109/L, and MPV 7.3 fL (normal 6.8–13.5 fL). Serum creatinine was 1452.2 μmol/L, consistent with ESRD. The patient was treated with intravenous dexamethasone 10 mg daily, intravenous immunoglobulin (IVIG) 25 g daily for 5 days, and multiple platelet transfusions. His platelet count gradually increased to 55 × 109/L. A right femoral vein catheter was placed for urgent hemodialysis, which was initiated on December 14, 2025. On December 24, 2025, he underwent an uncomplicated left forearm arteriovenous (AV) fistula creation under local anesthesia. On January 6, 2026, the patient developed purulent drainage from the AV fistula site. Surgical debridement and chronic ulcer repair were performed. Postoperatively, he developed recurrent severe infections including influenza A, Staphylococcus aureus bacteremia, and Klebsiella pneumoniae pneumonia, requiring prolonged broad-spectrum antibiotic therapy and admission to the intensive care unit (ICU). Given the persistent severe thrombocytopenia with normal MPV, poor response to standard ITP therapies, and recurrent life-threatening infections, an underlying primary immunodeficiency was suspected. Repeat CBC during infection showed profound lymphopenia (lymphocyte count 0.74 × 109/L) which was disproportionate to the degree of renal dysfunction. Quantitative flow cytometry revealed significantly reduced WASp expression in PBMCs (12% of normal control levels). Genetic diagnosis WES was performed and identified a novel heterozygous missense mutation in the WAS gene: c.252C > A (p.F84L). This variant was classified as a Variant of Uncertain Significance (VUS) according to ACMG criteria, with supporting evidence from PP3_Strong (computational predictions of pathogenicity) and PM2_Supporting (absent from population databases). Sanger sequencing confirmed the presence of the c.252C > A mutation in the patient and demonstrated that his mother was a heterozygous carrier, consistent with X-linked recessive inheritance (Fig. 1). Bone marrow findings Detailed BMA analysis performed on December 22, 2025, showed:1) Bone marrow cellularity: 80–90% (normal for age); 2) Myeloid series: 59.0% of nucleated cells, with normal maturation; 3) Erythroid series: 22.5% of nucleated cells, with normal maturation; 4) Myeloid:erythroid ratio: 2.62:1 (normal 2–4:1); 5) Megakaryocytes: >300 per low-power field (markedly increased), all of which were granular megakaryocytes with no mature platelet-producing megakaryocytes identified; 6) Platelets: markedly decreased on smear; 7) Lymphocytes: 14.5% of nucleated cells, with normal morphology. Flow cytometric immunophenotyping confirmed the morphologic findings, showing no immunophenotypic abnormalities in myeloid, lymphoid, or monocytic populations. These findings were consistent with megakaryocytic hyperplasia with maturation arrest, a pattern typically seen in ITP but also observed in WAS. Planned transplantation strategy Based on the confirmed diagnosis of WAS, the original treatment plan of isolated kidney transplantation was revised to a sequential combined transplantation approach. First stage: Allogeneic HSCT Donor: The patient's mother, who is a 5/10 HLA-haploidentical carrier of the WAS mutation; Conditioning regimen: Myeloablative conditioning with fludarabine (160 mg/m2), busulfan (12.8 mg/kg), and cyclophosphamide (120 mg/kg), plus rabbit anti-thymocyte globulin (ATG, 10 mg/kg) for in vivo T-cell depletion; Graft source: Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs) with CD34+ positive selection (ex vivo T-cell depletion); Graft-versus-host disease (GVHD) prophylaxis: Tacrolimus plus mycophenolate mofetil (MMF); Post-HSCT management: The patient will continue maintenance hemodialysis throughout the HSCT period and until renal transplantation. Second stage: Living donor kidney transplantation Timing: 6–12 months after successful HSCT, once complete donor chimerism is confirmed and immune function has normalized. Donor: Same haploidentical mother (the HSCT donor) Immunosuppression: Short-term low-dose tacrolimus monotherapy for 3–6 months, with planned discontinuation thereafter due to expected immune tolerance to the donor kidney. Discussion This case describes a novel presentation of WAS caused by a c.252C > A (p.F84L) mutation, characterized by normal platelet volume and late onset of severe complications. The patient was misdiagnosed with ITP for 25 years, which delayed appropriate management and led to the development of ESRD from IgA nephropathy. Classic WAS is universally associated with microthrombocytopenia (MPV <7.5 fL), which results from defective platelet production and accelerated clearance due to abnormal cytoskeletal structure [2]. However, our patient consistently had normal MPV (7.3–9.3 fL) throughout his clinical course, which is a well-recognized but underappreciated atypical presentation of WAS. Recent studies have identified several WAS mutations associated with normal platelet volume, most of which are missense mutations that preserve partial WASp function [4,5]. The c.252C > A (p.F84L) mutation in our patient is located in the EVH1 domain of WASp, which mediates interactions with proline-rich ligands including WIP (WASp-interacting protein). Partial preservation of WIP binding may stabilize WASp expression and maintain normal platelet volume regulation, while still impairing other critical functions of the protein leading to immune dysregulation. This case emphasizes that normal platelet volume does not exclude the diagnosis of WAS. WAS should be strongly considered in all male patients with chronic thrombocytopenia who have a poor response to standard ITP therapies, particularly if they have a history of recurrent infections, autoimmune disease, or kidney involvement. Approximately 19% of WAS patients develop clinically significant kidney disease, with IgA nephropathy being the most common histologic subtype [3]. The pathogenesis of IgA nephropathy in WAS is thought to result from impaired mucosal immunity leading to abnormal glycosylation of IgA1 and formation of immune complexes that deposit in the glomerular mesangium. Our patient developed biopsy-suspected IgA nephropathy at 24 years of age, which progressed rapidly to ESRD over 6 years. This accelerated course may have been exacerbated by chronic systemic inflammation and immune dysregulation associated with undiagnosed and untreated WAS. Importantly, isolated kidney transplantation in WAS patients is associated with poor long-term outcomes, with high rates of recurrent IgA nephropathy in the allograft and life-threatening infections due to chronic immunosuppression [8]. For WAS patients with ESRD, combined HSCT and kidney transplantation is the only curative treatment approach that addresses both the underlying immune defect and renal failure. Bertaina et al. [7] reported excellent outcomes in 10 pediatric patients with primary immunodeficiencies and ESRD who underwent combined transplantation, with 100% overall survival and 90% renal allograft survival at a median follow-up of 34 months. Most patients were able to discontinue all immunosuppressive therapy within 1 year of transplantation. Our planned sequential approach of HSCT followed by kidney transplantation from the same haploidentical donor has several theoretical advantages: Correction of the underlying immune defect before renal transplantation reduces the risk of perioperative infections; Establishment of complete donor chimerism after HSCT induces immunological tolerance to the donor kidney, allowing for minimal or no long-term immunosuppression; Sequential transplantation avoids the increased morbidity associated with simultaneous performance of two major surgical procedures.This strategy is particularly suitable for our patient, who has no suitable HLA-matched unrelated donor but has a willing haploidentical family donor. Conclusion We report a novel WAS mutation (c.252C > A, p.F84L) causing an atypical presentation with normal platelet volume, leading to 25 years of misdiagnosis as ITP and subsequent development of ESRD from IgA nephropathy. This case highlights the importance of considering WAS in male patients with chronic thrombocytopenia and poor response to ITP therapy, even in the absence of microthrombocytopenia. For WAS patients with ESRD, sequential HSCT followed by kidney transplantation from the same donor offers a potentially curative approach that addresses both the immune defect and renal failure. Ethical and publication statements Written informed consent for the publication of this case report and any accompanying images was obtained from the patient. The authors declare no conflicts of interest. The authors declare that the research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declared that the study followed the declaration of Helsinki and the declaration of Istanbul. The authors declared that the Shanxi Bethune Hospital does not require ethical approval for reporting individual cases or case series. This work has not been published previously and is not under consideration elsewhere. All authors have read and approved the final version of the manuscript. CRediT authorship contribution statement Guan Zhaojie: Investigation, Writing – original draft. Chen Hua: Data curation, Writing – review & editing. Wu Zhenghua: Resources, Writing – review & editing. Zhao Pengfei: Methodology, Writing – review & editing. Tong Xunan: Validation, Writing – review & editing. Wu Kang: Investigation, Writing – review & editing. Zhou Tianyu: Investigation, Writing – review & editing. Liu Bin: Conceptualization, Project administration, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.